MORF News and Press, Morphic Holding Inc. From 11/04/21

Morphic (NASDAQ:MORF): Q3 GAAP EPS of -$0.69 beats by $0.07. Revenue of $3.12M (-87.9% Y/Y) misses by $2.07M. Press Release For further details see: Morphic EPS beats by $0.07, misses on revenue

MORF-057 phase 1 safety, receptor occupancy, PK and mechanistic measures exceeded objectives; phase 2 program in ulcerative colitis expected to begin 1Q22 Announced appointment of Nisha Nanda, Ph.D., to Morphic Board of Directors WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWI...

Morphic is pursuing a multi-billion opportunity of replacing biologics modulating integrins with small molecules. The company is founded by the individual who discovered integrins and has built a unique technology platform to design selective oral therapies for integrins. Morphic ...

WALTHAM, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of the Morphic leadership team are scheduled t...

WALTHAM, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced participation in the following investor conferences: ...

Bryant Riley makes his largest purchase of B. Riley. Multiple insiders purchase shares of Ball Corporation. Insider buying and selling decreased last week. For further details see: Insider Weekends: Bryant Riley's Largest Purchase Of B. Riley

WALTHAM, Mass., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the appointment of Nisha Nanda, Ph.D., to its Boar...

MORF-057 phase 1 safety, receptor occupancy, PK and mechanistic measures exceeded objectives; phase 2 program expected to begin 1Q22 Presented positive preclinical data from αvβ8 program at AACR Annual Meeting demonstrating anti-tumor activity in checkpoint ref...

Mario13/E+ via Getty Images IDEXX downgraded Heska, Covetrus upgraded at Guggenheim With its mid-year rating changes, Guggenheim makes no adjustments to its positive views on animal health space. However, noting the bullish prospects in diagnostics, the analysts have upgraded Heska (HSKA) and...

janiecbros/E+ via Getty Images Biotech M&A is poised to heat up again as shares of the SPDR S&P Biotech’s (XBI) have fallen about 25% from their February highs, according to Jefferies. Biotech deals may pick up after a 3-6 month of a large "drawdown" and as prices "normalize" f...